Market news

ICCM's NMPA approval for ProSense opens China to commercialization, expanding its global regulatory footprint and long-term revenue opportunity.

Detailed price information for Icecure Medical Ltd Ord (ICCM-Q) from The Globe and Mail including charting and trades.

The arrangement with Scovas Medical is intended to support market development and physician access in the Netherlands.

Company reports strong commercial momentum with expanding gross margins and advancing CHoICE study, despite widening net loss.

Detailed price information for Icecure Medical Ltd Ord (ICCM-Q) from The Globe and Mail including charting and trades.

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today highlighted two recent peer-reviewed publications by leading U.S. experts that reinforce the growing clinical role of cryoablation in breast cancer treatment de-escalation. A new review cites ProSense®'s U.S. Food and Drug Administration ("FDA") marketing authorization, its inclu

Moby summary of IceCure Medical Ltd's Q2 2026 earnings call

Motley Fool Press Release.

--IceCure Medical Ltd., developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today reported financial and operational results as of and for the six months ended June 30, 2026. Increasing disposable probe sales continue to demonstrate that commercial adoption extends beyond...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Detailed price information for Icecure Medical Ltd Ord (ICCM-Q) from The Globe and Mail including charting and trades.

Detailed price information for Icecure Medical Ltd Ord (ICCM-Q) from The Globe and Mail including charting and trades.

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the six months ended June 30, 2026 before the Nasdaq Stock Market opens on Wednesday, August 12, 2026. The Company will also discuss such results and other corporate developments

--IceCure Medical Ltd., developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the Society of Interventional Oncology has submitted a formal petition to the National Comprehensive Cancer Network Breast Cancer Guidelines Panel, requesting the inclusion of...

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the West Cancer Center & Research Institute in Germantown, Tennessee will serve as the first U.S. clinical site for the Company's post-marketing study "ChoICE," (the "ChoICE Study"), for ProSense® in the treatment of low-risk breast cancer following U.S Food and Dr

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive liquid nitrogen-based cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the expansion of its United States ("U.S.") sales and marketing teams.

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today highlighted the growing international interest in its ProSense™ system in Brazil at the Simpósio de Radiologia Intervencionista em Oncologia ("SOBRICE Onco 2026"), one of the country's leading interventional oncology congresses.